Investment from Flagship Ventures Brings Red Rock Biofuels Closer to Construction of its First Commercial Biofuel Refinery

Investment from Flagship Ventures Brings Red Rock Biofuels Closer to Construction of its First Commercial Biofuel Refinery

March 17, 2015

Fort Collins, CO – March 17, 2015 – Red Rock Biofuels LLC, a pioneer in renewable biofuels, today unveiled a strategic partnership with Flagship Ventures that sets the stage for the construction of its first commercial scale refinery in Lakeview, OR. As part of this partnership, Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, will invest in Red Rock, assume a seat on the Board of Directors and serve as a strategic advisor for future fundraising efforts.

Moderna Appoints Tal Zaks, Former Head of Sanofi Global Oncology, as Chief Medical Officer

Moderna Appoints Tal Zaks, Former Head of Sanofi Global Oncology, as Chief Medical Officer

March 16, 2015

CAMBRIDGE, Mass., March 16, 2015 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™ across a range of therapeutic applications, announced today that Tal Zaks, M.D., Ph.D., will join Moderna’s executive leadership team as chief medical officer, effective March 16.

Prior to joining Moderna, Dr. Zaks was senior vice president and head of Global Oncology at Sanofi, where he was responsible for all aspects of oncology drug discovery, development and commercialization.

Concert Pharmaceuticals Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor for Cystic Fibrosis

Concert Pharmaceuticals Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor for Cystic Fibrosis

March 12, 2015

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that is has initiated its Phase 1 clinical program for deuterium-modified ivacaftor, a novel, potentially disease-modifying treatment for cystic fibrosis. Ivacaftor is commercially available under the name Kalydeco®. The first Phase 1 trial will be a crossover study to compare two proprietary deuterium-modified compounds in order to select one for further clinical evaluation.

BIND Therapeutics Appoints Andrew Hirsch as Acting President and Chief Executive Officer

BIND Therapeutics Appoints Andrew Hirsch as Acting President and Chief Executive Officer

March 10, 2015

- Additional organization changes and key hires further strengthen BIND leadership team -

- Scott Minick returns to career on West Coast after five years in leadership role -

Eleven Biotherapeutics Reports Fourth Quarter and Year-End 2014 Financial Results

Eleven Biotherapeutics Reports Fourth Quarter and Year-End 2014 Financial Results

March 4, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2014.

Quanterix Expands Kevin Hrusovsky’s Role to CEO

Quanterix Expands Kevin Hrusovsky’s Role to CEO

March 4, 2015

Life Science and Diagnostics Veteran to lead Quanterix in Driving Growth of its Disruptive Technology

Quanterix Corporation (“Quanterix”), a leader in ultrasensitive single molecule measurement for the benefit of human health, today announced the appointment of Kevin Hrusovsky as Chief Executive Officer (“CEO”). Mr. Hrusovsky will continue to serve as Executive Chairman of its Board of Directors.

Acceleron Presents Encouraging Response Rates and Progression-Free Survival Data in Patients with Advanced Renal Cell Carcinoma at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium

Acceleron Presents Encouraging Response Rates and Progression-Free Survival Data in Patients with Advanced Renal Cell Carcinoma at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium

February 28, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today reported new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma (RCC).

Acceleron Pharma Reports Fourth Quarter and Year Ended 2014 Financial and Operational Results

Acceleron Pharma Reports Fourth Quarter and Year Ended 2014 Financial and Operational Results

March 2, 2015

- Phase 2 data from luspatercept trials in β-thalassemia and MDS patients given as oral presentations at ASH and MDS abstract included in "Best of ASH" session -

- Plans with Celgene to initiate phase 3 clinical trials in both β-thalassemia and MDS in 2015 -

- Sotatercept slowed the progression of vascular calcification in patients with end stage kidney disease -

Acceleron Pharma Announces Executive Appointments and Promotions

Acceleron Pharma Announces Executive Appointments and Promotions

March 6, 2015

- Steven Ertel named Executive Vice President and Chief Operating Officer -

- Matthew Sherman, M.D. named Executive Vice President and Chief Medical Officer -

Editas Medicine Reports New Data Demonstrating Potential of CRISPR/Cas9 Construct as Novel Gene Repair Mechanism

Editas Medicine Reports New Data Demonstrating Potential of CRISPR/Cas9 Construct as Novel Gene Repair Mechanism

March 2, 2015

Oral presentation at Keystone Symposium for Genomic Instability and DNA Repair Highlights Potential for Use in Sickle Cell Anemia Mutation